Skip to search formSkip to main contentSkip to account menu

ALX-0600

Known as: ALX 0600 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Glucagon-Like Peptide 2
teduglutide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Continuous Intravenous Administration of Teduglutide (ALX-0600), a Glucagon-like Peptide-2 (GLP-2) Analog Induces Intestinotrophic Activity: 250
2003
2003
ALX-0600, a glucagon-like peptide-2 analogue, protects small intestinal stem cells from radiation damage
2001
2001
ALX-0600 (NPS Allelix Corp).
NPS Allelix (formerly Allelix Biopharmaceuticals) is developing the glucagon-like peptide 2 (GLP-2) analog ALX-0600 for the… 
Review
2001
Review
2001
ALX-0600 (NPS Allelix Corp).
NPS Allelix (formerly Allelix Biopharmaceuticals) is developing the glucagon-like peptide 2 (GLP-2) analog ALX-0600 for the… 
2001
2001
ALX-0600: A potent glucagon-like peptide-2 receptor agonist
Highly Cited
2000
Highly Cited
2000
Hormonal therapy for short bowel syndrome.
2000
2000
An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects
2000
2000
The ntestinotrophic properties of ALX-0600, a glucagon-like peptide-2 analogue
2000
2000
The barrier function of intestinal endothelium is enhanced by ALX-0600,
  • 2000
  • Corpus ID: 195138911
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)